Department of Scientific Research, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Anhui Public Health Clinical Center, Hefei, Anhui, People's Republic of China.
Drug Des Devel Ther. 2023 Jul 19;17:2107-2118. doi: 10.2147/DDDT.S411211. eCollection 2023.
Diabetic nephropathy (DN), as a chronic inflammatory complication of diabetes, is characterized by hyperglycemia, albuminuria and edema, which ultimately becomes the leading cause of end-stage renal disease (ESRD). Astragalus polysaccharide (APS), extracted from the , was widely used in the treatment of diabetes mellitus. However, the functional roles of APS ameliorate inflammatory responses in DN, which remain poorly understood. Therefore, the purpose of this study was to explore the molecular mechanism of APS on DN in vivo and vitro models.
We explored the beneficial effects of APS in streptozotocin (STZ)-induced DN rat model and high glucose (HG)-treated glomerular podocyte model. The fasting blood glucose (FBG) and ratio of kidney weight to body weight were measured after 4 weeks of APS treatment. The renal injury parameters containing serum creatinine (Scr), blood urea nitrogen (BUN) and 24 h urinary protein were evaluated. The renal pathological examination was observed by hematoxylin-eosin (HE) staining. The levels of IL-1β, IL-6 and MCP-1 were evaluated by ELISA assay. The proliferation of podocytes was determined using CCK-8 assay and flow cytometry. qRT-PCR and Western blot analysis were performed to determine the amounts of TLR4/NF-κB-related gene expression.
Our results indicated that APS effectively decreased the levels of FBG, BUN, Scr and renal pathological damage when compared with STZ-induced DN model group. Additionally, APS significantly ameliorated renal injury by reducing inflammatory cytokines IL-1β, IL-6, MCP-1 expression and inhibiting the TLR4/NF-κB pathway activity in DN rats. Consistent with the results in vitro, the HG-induced inflammatory response and proliferation of glomerular podocytes were also alleviated through APS administration.
We found that APS ameliorated DN renal injury, and the mechanisms perhaps related to relieving inflammatory responses and attenuating the TLR4/NF-κB signaling pathway.
糖尿病肾病(DN)是糖尿病的一种慢性炎症并发症,其特征为高血糖、蛋白尿和水肿,最终成为终末期肾病(ESRD)的主要原因。黄芪多糖(APS)是从黄芪中提取的,广泛用于治疗糖尿病。然而,APS 改善 DN 中炎症反应的功能作用仍知之甚少。因此,本研究旨在探讨 APS 在体内和体外 DN 模型中的分子机制。
我们在链脲佐菌素(STZ)诱导的 DN 大鼠模型和高糖(HG)处理的肾小球足细胞模型中探索了 APS 的有益作用。APS 治疗 4 周后,测量空腹血糖(FBG)和肾重/体重比。评估血清肌酐(Scr)、血尿素氮(BUN)和 24 小时尿蛋白等肾损伤参数。通过苏木精-伊红(HE)染色观察肾组织病理学变化。通过 ELISA 测定法评估白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)和单核细胞趋化蛋白-1(MCP-1)的水平。使用 CCK-8 测定法和流式细胞术测定足细胞的增殖。qRT-PCR 和 Western blot 分析用于确定 TLR4/NF-κB 相关基因表达的量。
我们的结果表明,与 STZ 诱导的 DN 模型组相比,APS 可有效降低 FBG、BUN、Scr 和肾组织病理学损伤水平。此外,APS 通过降低 DN 大鼠中炎症细胞因子 IL-1β、IL-6、MCP-1 的表达并抑制 TLR4/NF-κB 通路活性,显著改善了肾损伤。与体外结果一致,APS 给药也减轻了 HG 诱导的肾小球足细胞炎症反应和增殖。
我们发现 APS 改善了 DN 肾损伤,其机制可能与减轻炎症反应和抑制 TLR4/NF-κB 信号通路有关。